David Kirn

CIK: 0001834021

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)12 (80.0%)

Position reduction

Option Exercises (M)1 (6.7%)

Derivative conversions

Awards (A)2 (13.3%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

FDMT

4D Molecular Therapeutics, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (15 total)

FDMT
4D Molecular Therapeutics, Inc.
Oct 5, 2026
Sale(S)
Direct
58.1K shares at avg. $12.92$750K
FDMT
4D Molecular Therapeutics, Inc.
Oct 5, 2026
Sale(S)
Direct
272 shares at avg. $13.61$4K
FDMT
4D Molecular Therapeutics, Inc.
Sep 14, 2026
Sale(S)
Direct
58.3K shares at avg. $13.90$811K
FDMT
4D Molecular Therapeutics, Inc.
Aug 19, 2026
Sale(S)
Direct
25.9K shares at avg. $16.42$426K
FDMT
4D Molecular Therapeutics, Inc.
Aug 19, 2026
Sale(S)
Direct
43.1K shares at avg. $15.36$663K
FDMT
4D Molecular Therapeutics, Inc.
Aug 19, 2026
Exercise(M)
Direct
50K shares at avg. $4.14$207K
FDMT
4D Molecular Therapeutics, Inc.
Aug 4, 2026
Sale(S)
Direct
26.8K shares at avg. $10.23$275K
FDMT
4D Molecular Therapeutics, Inc.
Aug 3, 2026
Sale(S)
Direct
12.4K shares at avg. $10.05$125K
FDMT
4D Molecular Therapeutics, Inc.
Jul 10, 2026
Sale(S)
Direct
442 shares at avg. $12.84$6K
FDMT
4D Molecular Therapeutics, Inc.
Jul 10, 2026
Sale(S)
Direct
15.3K shares at avg. $12.01$184K
FDMT
4D Molecular Therapeutics, Inc.
Jul 9, 2026
Sale(S)
Direct
42.6K shares at avg. $12.87$548K
FDMT
4D Molecular Therapeutics, Inc.
Jun 22, 2026
Sale(S)
Direct
114.7K shares at avg. $10.47$1.2M
FDMT
4D Molecular Therapeutics, Inc.
Jun 1, 2026
Sale(S)
Direct
1.9K shares at avg. $10.02$19K
FDMT
4D Molecular Therapeutics, Inc.
Mar 25, 2026
Award(A)
Stock Option (Right to Buy)
Direct
750K shares-
FDMT
4D Molecular Therapeutics, Inc.
Mar 6, 2025
Award(A)
Stock Option (Right to Buy)
Direct
267.5K shares-

		Type	Shares	Price		Ownership
Oct 5, 2026	FDMT 4D Molecular Therapeutics, Inc.	Sale(S)	58,061	$12.92	$750,235	Direct
Oct 5, 2026	FDMT 4D Molecular Therapeutics, Inc.	Sale(S)	272	$13.61	$3,702	Direct
Sep 14, 2026	FDMT 4D Molecular Therapeutics, Inc.	Sale(S)	58,333	$13.90	$811,004	Direct
Aug 19, 2026	FDMT 4D Molecular Therapeutics, Inc.	Sale(S)	25,927	$16.42	$425,651	Direct
Aug 19, 2026	FDMT 4D Molecular Therapeutics, Inc.	Sale(S)	43,149	$15.36	$662,622	Direct
Aug 19, 2026	FDMT 4D Molecular Therapeutics, Inc.	Exercise(M)	50,000	$4.14	$207,000	Direct
Aug 4, 2026	FDMT 4D Molecular Therapeutics, Inc.	Sale(S)	26,842	$10.23	$274,596	Direct
Aug 3, 2026	FDMT 4D Molecular Therapeutics, Inc.	Sale(S)	12,415	$10.05	$124,722	Direct
Jul 10, 2026	FDMT 4D Molecular Therapeutics, Inc.	Sale(S)	442	$12.84	$5,673	Direct
Jul 10, 2026	FDMT 4D Molecular Therapeutics, Inc.	Sale(S)	15,283	$12.01	$183,560	Direct
Jul 9, 2026	FDMT 4D Molecular Therapeutics, Inc.	Sale(S)	42,608	$12.87	$548,177	Direct
Jun 22, 2026	FDMT 4D Molecular Therapeutics, Inc.	Sale(S)	114,746	$10.47	$1,200,851	Direct
Jun 1, 2026	FDMT 4D Molecular Therapeutics, Inc.	Sale(S)	1,922	$10.02	$19,258	Direct
Mar 25, 2026	FDMT 4D Molecular Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	750,000	-	-	Direct
Mar 6, 2025	FDMT 4D Molecular Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	267,500	-	-	Direct

1-15 of 15 transactions

About Kirn David

Kirn David (SEC CIK 0001834021) files insider reports with the SEC as Director of 4D Molecular Therapeutics, Inc. (FDMT).

Signal8 holds 10 ownership filings by Kirn David, all Form 4s, filed between Mar 10, 2025 and Oct 7, 2026. Those filings report 15 transactions, from Mar 6, 2025 to Oct 5, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Kirn David's filings is in EMERYVILLE, CA.

Recent filings by Kirn David

Oct 5, 2026: Open-market sales of FDMT shares (2 lines, Form 4, code S).
Sep 14, 2026: Open-market sale of FDMT shares (Form 4, code S).
Aug 19, 2026: Open-market sales of FDMT shares (2 lines, Form 4, code S).
Aug 19, 2026: Option exercise of FDMT shares (Form 4, code M).
Aug 4, 2026: Open-market sale of FDMT shares (Form 4, code S).

Other insiders filing for 4D Molecular Therapeutics, Inc. (FDMT)

Bizily Scott, Chief Legal Officer
Tomasello Shawn, Director
THEUER CHARLES, Director
Miller-Rich Nancy, Director
GRAY SUSANNAH, Director
MILLIGAN JOHN F, Director

How to read Form 4 transaction codes